Opendata, web and dolomites

MAMSCAN

New Method for Early Stage Breast Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAMSCAN project word cloud

Explore the words cloud of the MAMSCAN project. It provides you a very rough idea of what is the project "MAMSCAN" about.

stage    treatment    launch    health    gynecological    affordable    lower    competitors    economic    anatomic    ai    30    annually    initial    mu    acceptance    82    attain    france    ing    significantly    pointing    clinics    detection    finland    markets    services    million    certification    enhanced    day    accuracy    imaging    scanning    care    invasive    2016    age    population    deadliest    alternative    device    healthcare    first    solutions    uk    ultrasound    50    women    breast    groups    half    diagnosis    sales    price    extensive    mortality    private    outside    oy    patented    clients    pressure    diagnostic    societal    spain    clinical    fueled    imaqen    effect    cancer    preventive    share    ipr    acquisition    involve    decreased    commercialization    found    customers    proprietary    frequency    solution    considerable    direct    worked    foreseen    strategy    finnish    neutral    planning    images    acquire    suspect    business    map    market    smei    expensive    speed    76    mammography    radiating    fall    2020    doctor    examination    company    screenings    finalise    amiqo    consists    specialist    wavelength    sweden    2026    pipeline   

Project "MAMSCAN" data sheet

The following table provides information about the project.

Coordinator
IMAQEN OY 

Organization address
address: LIIKEHUONEISTO C JA D POHJOISRANTA 6 A
city: HELSINKI
postcode: 170
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.imaqen.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMAQEN OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

Imaqen Oy is a Finnish healthcare technology company developing an imaging solution for the early detection of breast cancer. Since 2016, we have worked on our proprietary technology, Amiqo that has the same diagnostic accuracy as the key competitors, mammography and breast ultrasound, while it is non-invasive and non-radiating. Amiqo consists of an imaging device using a patented μm-wavelength scanning, a proprietary frequency analysis enhanced by AI and an anatomic map pointing out the suspect areas for diagnosis carried out by a specialist doctor. Our initial target customers are private health care clinics who already have gynecological services. They are under pressure of finding affordable solutions for preventive healthcare fueled by women’s increasing awareness of the importance of early detection. The economic effect is considerable: the operating costs are significantly lower, it enables more images taken/day and its acquisition cost is neutral or lower. The end-clients are women under 50 or over 70 who fall outside the population level mammography screenings. 50% of breast cancer cases are found in these age groups annually. For women, Amiqo examination will be less than half the price of any current alternative. Through lower mortality and decreased treatment costs, Amiqo has a direct impact at societal level as breast cancer is the most common, the deadliest and the most expensive cancer for women in Europe. The next steps involve extensive clinical testing to finalise the product design, acquire certification and attain clinical acceptance. The SMEI funding will speed up the business planning in our priority markets, Finland, Sweden, France, the UK and Spain, including IPR pipeline, clinical acceptance strategy, user and technical requirements. The commercialization stage will be achieved by €1,76 million with the launch foreseen in 2020. The first goal is a 30% market share of the non-invasive imaging market by 2026 resulting in sales of €82 million.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMSCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMSCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More